A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nudemice

Limited options for the treatment of prostate cancer have spurred the searc h for new therapies. One innovative approach is the use of 1 alpha,25-dihyd roxyvitamin D-3 (calcitriol) analogues to inhibit cancer growth. We demonst rate here that the calcitriol analogue, EB1089, extensively inhibits the gr owth of LNCaP prostate cancer cells in culture and causes the cells to both accumulate in G(0)-G(1) and undergo apoptosis, Importantly, we found that EB1089 inhibits the growth of LNCaP tumor xenografts in nude mice. Because of these antiproliferative properties in vivo, EB1089 is a potential new th erapeutic agent for the treatment of prostate cancer.